Alcon Loses CEO And Eye Drugs After Dragging On Novartis Financials
This article was originally published in Scrip
Executive Summary
Novartis is set to overhaul its eye care business Alcon after a lackluster 2015, focusing on its core Surgical and Vision Care business by cleaving its ophthalmic pharmaceuticals business and repositioning it into the Pharmaceuticals division.